Articles by tag: glp-1

Intermittent Fasting: Why IF Is No Longer a Trend in 2026

Cochrane Review and Science Translational Medicine have proven: intermittent fasting is not more effective than regular diets. Find out why clean eating and GLP-1 are displacing IF.

EMA recommended the first oral GLP-1 drug for weight loss | Wegovy

EMA issued a positive opinion on the first oral GLP-1 Wegovy for weight loss. Analysis of efficacy, price, side effects and market forecast. Read details.

EMA approved the first oral GLP-1 drug Wegovy for weight control

EMA recommended the first GLP-1 tablet for weight loss — Wegovy (semaglutide) 25 mg. Efficacy up to 16.6% weight loss. Market analysis, winners and losers. Learn more.

Oral GLP-1 tablet for weight loss: EMA analysis

EMA decision analysis on oral semaglutide (Wegovy Pill). OASIS 4 data, investments in Ireland and competition with Lilly. Read forecasts and hidden risks.

GLP-1 changes eating habits: fast food crisis

GLP-1 drugs turn off 'food noise' and kill demand for fast food and snacks. Find out who wins and who loses billions in the new reality. Read the analysis.

Fibermaxing: a natural alternative to Ozempic in 2026

Fibermaxing — the 2026 trend: how fiber is replacing GLP-1 injections and changing the market. Find out who is making money and who is threatened by the new dietary standard.